| Literature DB >> 30373159 |
Vuanghao Lim1,2, Edward Schneider3, Hongli Wu4,5, Iok-Hou Pang6,7.
Abstract
Cataract is an eye disease with clouding of the eye lens leading to disrupted vision, which often develops slowly and causes blurriness of the eyesight. Although the restoration of the vision in people with cataract is conducted through surgery, the costs and risks remain an issue. Botanical drugs have been evaluated for their potential efficacies in reducing cataract formation decades ago and major active phytoconstituents were isolated from the plant extracts. The aim of this review is to find effective phytoconstituents in cataract treatments in vitro, ex vivo, and in vivo. A literature search was synthesized from the databases of Pubmed, Science Direct, Google Scholar, Web of Science, and Scopus using different combinations of keywords. Selection of all manuscripts were based on inclusion and exclusion criteria together with analysis of publication year, plant species, isolated phytoconstituents, and evaluated cataract activities. Scientists have focused their attention not only for anti-cataract activity in vitro, but also in ex vivo and in vivo from the review of active phytoconstituents in medicinal plants. In our present review, we identified 58 active phytoconstituents with strong anti-cataract effects at in vitro and ex vivo with lack of in vivo studies. Considering the benefits of anti-cataract activities require critical evaluation, more in vivo and clinical trials need to be conducted to increase our understanding on the possible mechanisms of action and the therapeutic effects.Entities:
Keywords: cataract; drug discovery; lens; phytoconstituents; preclinical models
Mesh:
Substances:
Year: 2018 PMID: 30373159 PMCID: PMC6265913 DOI: 10.3390/nu10111580
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow chart of review process in article selection.
Summary of relevant in vitro anti-cataract activities of phytoconstituents.
| Active Ingredient | Structure | IC50 Values | ||||||
|---|---|---|---|---|---|---|---|---|
| AGE | ARI | GLWW | RHAR | BLAR | HLAR | RLAR | ||
| 1- |
| NA | NA | NA | 17.00 µM [ | NA | NA | NA |
| 1,3-di- |
| 24.85 µM [ | NA | NA | 0.810 µM [ | NA | NA | 0.22 µM [ |
| 1,5-Di-hydroxy-1,5-di-[( |
| NA | NA | NA | 194.67µM [ | NA | NA | NA |
| 1,5-di- |
| NA | NA | NA | NA | NA | NA | 2.98 µM [ |
| 1,3,6-trihydroxy-2-methoxymethylanthraquinone |
| 52.72 µM [ | NA | NA | NA | NA | NA | 3.04 µM [ |
| 1,2,3,6-tetra- |
| 1.99 µM [ | NA | NA | NA | NA | NA | 0.70 µM [ |
| 1,3,5,8-Tetrahydroxyxanthone |
| NA | NA | NA | NA | NA | NA | 0.0886 μM [ |
| 2″,4″- |
| 11.46 µM [ | NA | NA | NA | NA | NA | 0.077 µM [ |
| 3-Isomangostin |
| NA | NA | NA | NA | NA | NA | 3.48 μM [ |
| 3′,5′-dimethoxy-(1,1′-biphenyl)-3,4-diol 3- |
| NA | NA | NA | NA | NA | NA | 3.80 µM [ |
| 3,5-di- |
| 6.06 µM [ | NA | 153 g [ | 1.34 µM [ | NA | NA | 0.19 µM [ |
| 4- |
| 10.80 µM [ | NA | NA | NA | NA | NA | 36.20 µM [ |
| 4,5-Di- |
| NA | NA | NA | NA | NA | NA | 0.29 µM [ |
| 5- |
| NA | NA | NA | NA | NA | NA | 14.19 µM [ |
| 5,7,4′-trihydroxyisoflavone (Genistein) |
| NA | NA | NA | NA | NA | NA | 9.48 µM [ |
| 20( |
| NA | NA | NA | 147.40 µM [ | NA | NA | NA |
| Acteoside |
| 5.11 µM [ | NA | NA | NA | NA | NA | 0.83 µM [ |
| Basilicumin [7-(3-hydroxypropyl)-3-methyl-8- |
| NA | NA | NA | NA | 2.09 µM | NA | NA |
| Caffeic acid |
| 7.56 µM [ | NA | NA | 210.28µM [ | NA | NA | 16.71 µM [ |
| Canangafruiticoside E | NA | NA | NA | NA | NA | NA | 0.80 µM [ | |
| Capsofulvesin A [((2 |
| NA | NA | NA | NA | NA | NA | 52.53 µM [ |
| Davallialactone |
| NA | NA | NA | 0.56 µM [ | NA | NA | 0.33 µM [ |
| Delphinidin 3- | NA | NA | NA | NA | NA | NA | 0.37 µM [ | |
| Desmethylanhydroicaritin |
| 294.60 µM [ | NA | NA | 0.45 µM [ | NA | NA | 0.95 µM [ |
| Ellagic acid |
| 26.0 µM [ | NA | 42.47% [ | NA | NA | 1.37 µM [ | 0.12 µM [ |
| Epiberberine |
| NA | NA | NA | 168.10 µM [ | NA | NA | 100.07 µM [ |
| Geraniin |
| 21.00 µM | 0.15 µM [ | 39.87% [ | NA | NA | NA | NA |
| Hipolon |
| NA | NA | NA | NA | NA | NA | 9.47 µM [ |
| Hirsutrin |
| NA | NA | 33.78% [ | NA | NA | NA | 4.78 µM [ |
| Hopeafuran |
| NA | NA | NA | NA | NA | NA | 14.80 µM [ |
| Hypolaetin 7- |
| NA | 0.66 µM [ | NA | NA | NA | NA | NA |
| Isocampneoside II |
| NA | NA | NA | 9.72 µM [ | NA | NA | NA |
| Kaempferol |
| 36.01 µM [ | NA | NA | 45.58 µM [ | NA | NA | 1.10 µM [ |
| Kakkalide |
| NA | NA | NA | NA | NA | NA | 0.56 µM [ |
| Lucidumol A [(24 |
| NA | NA | NA | NA | 19.10 µM [ | NA | NA |
| Lupeol |
| NA | NA | NA | 3.60 µM [ | NA | NA | NA |
| Luteolin (2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-chromomenone) |
| 16.60 µM [ | NA | NA | 6.34 µM [ | NA | NA | 0.087 µM [ |
| Luteolin-7- |
| 117.80 µM [ | NA | NA | NA | NA | NA | 7.34 µM [ |
| Magnoflorine |
| NA | NA | NA | NA | NA | NA | 3.60 µM [ |
| Methyl-3,5-di- |
| NA | NA | 117 g [ | 0.67 µM [ | NA | NA | 0.30 µM [ |
| Mumeic acid-A |
| NA | NA | NA | NA | NA | NA | 0.40 µM [ |
| Palbinone |
| >500 µM [ | NA | NA | NA | NA | NA | 11.40 µM [ |
| Puerariafuran |
| NA | NA | NA | NA | NA | NA | 22.20 µM [ |
| Quercetin-3- |
| >1000 µM [ | NA | NA | NA | NA | NA | 2.21 µM [ |
| Quercitrin (Quercetin 3- |
| 4.20 µM [ | NA | NA | NA | NA | NA | 0.17 µM [ |
| Rhetsinine |
| NA | NA | NA | NA | NA | NA | 24.10 µM [ |
| Rosmarinic acid |
| NA | NA | 532.38g [ | 2.77 µM [ | NA | NA | 0.30 µM [ |
| Scopoletin |
| 2.93 µM [ | NA | NA | NA | NA | NA | 2.59 µM [ |
| Semilicoisoflavone B |
| NA | NA | NA | 10.60 µM [ | NA | NA | 1.80 µM [ |
| Sulfuretin |
| 124.00 µM [ | NA | NA | 1.30 µM [ | NA | NA | NA |
| Syringic Acid |
| NA | NA | NA | NA | NA | NA | 1081.1 µm [ |
| Swertisin (C-glycosidic flavonoid) | NA | NA | NA | NA | NA | NA | 1.60 µm [ | |
| Valoneic acid dilactone |
| NA | NA | NA | NA | NA | NA | 0.075 µM [ |
Summary of relevant ex vivo and in vivo activities of phytoconstituents.
| Constituent Name | Structure | Doses (IC50/EC50) | |||||
|---|---|---|---|---|---|---|---|
| AR Transgenic Mice | Selenite-Induced | AR Rat Lens | Galactose-Induced Lens Opacity | Xylose-Induced Lens Opacity | Ref | ||
| 1- |
| Ex vivo: 30.00 µM | NA | NA | NA | NA | [ |
| 1,2,3,6-Tetra- |
| NA | NA | NA | NA | Ex vivo: 80.00 µM | [ |
| 3,5-di- |
| NA | NA | NA | NA | Ex vivo: 10.00 μM | [ |
| 5,7,4′-trihydroxyisoflavone (Genistein) |
| NA | NA | NA | NA | Ex vivo: 18.50 µM | [ |
| Isorhamnetin-3-glucoside |
| NA | Ex vivo: 52.25 µM | NA | NA | NA | [ |
| Lupeol |
| NA | In vivo: 126.15 μM | NA | NA | NA | [ |
| Luteolin (2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-chromomenone) |
| NA | Ex vivo: 6.98 µM | NA | NA | NA | [ |
| Puerariafuran |
| NA | NA | NA | NA | Ex vivo: 15.00 µM | [ |
| Scopoletin |
| NA | NA | NA | NA | Ex vivo: 25.00 µM | [ |
| Syringic acid |
| NA | NA | NA | Ex vivo: 1075.70 μM | NA | [ |